Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $22.51, but opened at $23.56. Chugai Pharmaceutical shares last traded at $23.11, with a volume of 42,987 shares changing hands.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on CHGCY. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group cut shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.
Check Out Our Latest Analysis on Chugai Pharmaceutical
Chugai Pharmaceutical Stock Performance
The company has a market cap of $76.06 billion, a PE ratio of 24.07 and a beta of 0.60. The business’s 50-day moving average is $20.81 and its 200 day moving average is $24.29.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported $0.27 earnings per share for the quarter. The company had revenue of $2.54 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Chugai Pharmaceutical had a return on equity of 24.91% and a net margin of 35.63%. Equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 EPS for the current fiscal year.
About Chugai Pharmaceutical
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.
Recommended Stories
- Five stocks we like better than Chugai Pharmaceutical
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
